Skip to main content
. 2022 Mar 24;10(4):759. doi: 10.3390/biomedicines10040759

Table 2.

Comparison between patients with HRs to ICM and patients with HRs to GBCM.

HRs 1 to ICM 2 HRs to GBCM 3 p-Value
Patients (n°) 278 65
Age (years) at the first evaluation (median, ±SD) 59 (±16) 47 (±16) <0.01 *
Total HRs (n°, %) 289 (79) 72 (20) N.S. *
IHRs (n°, %) 226 (77) 61 (21) N.S. *
NIHRs (n°, %) 63 (85) 11 (15) N.S. *
Comorbid allergic/hypersensitivity **
Allergic rhino-conjunctivitis (n°, %) 47 (16.7) 15 (21.7) N.S.
Angioedema (n°, %) 7 (2.5) 1 (1.4) N.S.
Asthma (n°, %) 15 (5.3) 10 (14.5) <0.05
Contact allergy (n°, %) 17 (6) 9 (13) N.S.
Drug allergy (n°, %) 9 (3.2) 2 (2.9) N.S.
Food allergy (n°, %) 5 (1.8) 6 (8.7) <0.01
Idiopathic anaphylaxis (n°, %) 1 (0.3) - -
Hymenoptera allergy (n°, %) 1 (0.3) 1 (1.4) N.S.
Mastocytosis (n°, %) 3 (1.1) - -
Non-allergic drug hypersensitivity (n°, %) 77 (27.4) 32 (46.4) <0.01
Non-allergic food reactions (n°, %) 19 (6.8) 5 (7.2) N.S.
Urticaria (n°, %) 10 (3.5) 6 (8.7) N.S.
Urticaria + angioedema (n°, %) - 1 (1.4) -
Comorbid non-allergic diseases **
Autoimmunological disease (n°, %) 21 (7.5) 6 (8.7) N.S.
Cardiovascular/heart disease (n°, %) 78 (27.7) 4 (5.8) <0.01
Gastrointestinal disease (n°, %) 64 (22.8) 13 (18.8) N.S.
Hematologic disease (n°, %) 10 (3.5) 3 (4.3) N.S.
History of cancer (n°, %) 159 (56.6) 28 (40.6) <0.05
Neurologic disease (n°, %) 31 (11) 16 (23.2) <0.05
Psychiatric disorder (n°, %) 21 (7.5) 5 (10.1) N.S.
Renal disease (n°, %) 7 (2.5) 1 (1.4) N.S.

1: HRs = hypersensitivity reactions; 2: ICM = iodinated contrast media; 3: GBCM = gadolinium-based contrast media; *: Mann–Whitney U test; **: chi-square test; : The sum of percentages does not include reactions to unknown contrast media.